Opinion
15dOpinion
Why raising NHS spending on new drugs by 25% is the wrong decision – health economist’s view
This change has come from wider government concerns over protecting UK-based pharmaceutical manufacturing, and now from pressure to open up the UK market to US drug companies. Shifting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results